Status:
RECRUITING
Positive Association of US-FLI With the Severity of CAD
Lead Sponsor:
Chongqing Medical University
Conditions:
Coronary Artery Disease of Significant Bypass Graft
Metabolic Dysfunction-associated Fatty Liver Disease
Eligibility:
All Genders
18-90 years
Brief Summary
As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indi...
Detailed Description
204 patients who had invasive coronary angiography performed between July 2022 and December 2023 at the cardiology department of the Second Affiliated Hospital of Chongqing Medical University were inc...
Eligibility Criteria
Inclusion
- Patients older than 18 years old
- Patients underwent ICA due to chest pain, chest tightness or other reasons in our hospital from August 2022 to December 2023 were included in our study
Exclusion
- Incomplete clinical data
- previous coronary stent implantation
- no abdominal ultrasound examination
- poor ultrasound image quality
- congenital heart disease
- tumor
- thyroid diseases and infectious diseases
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 28 2025
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT06541132
Start Date
July 1 2022
End Date
April 28 2025
Last Update
August 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400000